Skip to content

Bio-Rad Laboratories BIO Net Investment in Lease

Net Investment in Lease at other companies

Abbott logo
AbbottABT
Danaher logo
DanaherDHR
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA
TEC
Bio-TechneTECH
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories's net investment in lease?
Bio-Rad Laboratories (BIO) reported net investment in lease of $161.9M in Q1 2026.
How has Bio-Rad Laboratories's net investment in lease changed year-over-year?
Bio-Rad Laboratories's net investment in lease increased by 5.7% year-over-year, from $153.2M to $161.9M.
What is the long-term trend for Bio-Rad Laboratories's net investment in lease?
Over 5 years (2020 to 2025), Bio-Rad Laboratories's net investment in lease has grown at a -3.4% compound annual growth rate (CAGR), from $202.14M to $170M.